NEW YORK (GenomeWeb) – RNA products developer Cofactor Genomics announced today that it has acquired San Francisco-based biomarker development company Narus Biotechnologies.

The acquisition of Narus — which has been focused on creating RNA-based diagnostics for neurological diseases such as Alzheimer's and Parkinson's — will help Cofactor to further expand into the realm of RNA diagnostics, and to develop its plans to create RNA-based tests for cancer and neurodegenerative diseases, the company said.

Terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.